



US009078465B2

(12) **United States Patent**  
**Vanden Berghe**(10) **Patent No.:** **US 9,078,465 B2**(45) **Date of Patent:** **\*Jul. 14, 2015**(54) **CHOLINE-SILICIC ACID COMPLEX WITH OSMOLYTES AND DIVALENT TRACE ELEMENTS**(75) Inventor: **Dirk André R. Vanden Berghe**, Laarne (BE)(73) Assignee: **Bio Minerals N.V.**, Destelbergen (BE)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 381 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/113,832**(22) Filed: **May 23, 2011**(65) **Prior Publication Data**

US 2012/0015047 A1 Jan. 19, 2012

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 10/508,168, filed as application No. PCT/EP03/03175 on Mar. 20, 2003, now Pat. No. 7,968,528.

(30) **Foreign Application Priority Data**

Mar. 20, 2002 (EP) ..... 02076099

(51) **Int. Cl.**

**A61K 33/30** (2006.01)  
**A61K 33/32** (2006.01)  
**A23L 1/304** (2006.01)  
**A01N 59/00** (2006.01)  
**A23K 1/16** (2006.01)  
**A23K 1/175** (2006.01)  
**A23K 1/18** (2006.01)  
**A61K 9/00** (2006.01)  
**A61K 31/14** (2006.01)  
**A61K 31/695** (2006.01)  
**A61K 33/00** (2006.01)  
**A61K 33/06** (2006.01)  
**A61K 45/06** (2006.01)  
**A61K 47/02** (2006.01)  
**A61K 47/18** (2006.01)  
**C05D 9/00** (2006.01)  
**C05G 3/00** (2006.01)

(52) **U.S. Cl.**CPC ..... **A23L 1/304** (2013.01); **A01N 59/00** (2013.01); **A23K 1/1609** (2013.01); **A23K**

**1/1756** (2013.01); **A23K 1/1758** (2013.01);  
**A23K 1/1826** (2013.01); **A61K 9/0095**  
(2013.01); **A61K 31/14** (2013.01); **A61K**  
**31/695** (2013.01); **A61K 33/00** (2013.01);  
**A61K 33/06** (2013.01); **A61K 45/06** (2013.01);  
**A61K 47/02** (2013.01); **A61K 47/18** (2013.01);  
**C05D 9/00** (2013.01); **C05G 3/0076** (2013.01)

(58) **Field of Classification Search**CPC ..... **A61K 33/30**; **A61K 33/32**  
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

4,466,958 A 8/1984 Morrison  
5,183,061 A 2/1993 Wiegand et al.  
5,840,881 A 11/1998 Uda et al.  
6,335,457 B1 1/2002 Seguin et al.  
2003/0049325 A1 3/2003 Suwelack et al.

**FOREIGN PATENT DOCUMENTS**

DE 43 22 939 A1 1/1995  
EP 0 158 120 A1 10/1985  
EP 0 573 876 A2 12/1993  
EP 1 110 909 A1 6/2001  
WO WO 95/21124 8/1995  
WO WO 96/23413 8/1996

**OTHER PUBLICATIONS**

Good, et al., Hydrogen ion buffers for biological research. Biochemistry. Feb. 1966;5(2):467-77.

Leifer, et al., Journal of American Chemical Society, 1957, vol. 79, pp. 5098-5101.

Subcommittee on Poultry Nutrition Nutrients Requirement of Poultry, Ninth Edition (1994) pp. 1-2.

*Primary Examiner* — Samira Jean-Louis(74) *Attorney, Agent, or Firm* — Bret E. Field; Bozicevic, Field & Francis LLP(57) **ABSTRACT**

The invention relates to a biological preparation comprising orthosilicic and silicic acid, a primary ("constant/first") osmolyte choline and a weak alkalizing agent without free hydroxyl groups and to a method for preparing the preparation, comprising: i) hydrolyzing a silicon comprising choline solution thereby forming a choline stabilized orthosilicic acid and oligomers solution; ii) alkalizing the choline orthosilicic acid and oligomers solution by adding a weak alkalizing agent without hydroxyl groups; and iii) optionally adding a divalent trace element and/or secondary osmolyte, to biological preparation obtainable and its uses.

**21 Claims, No Drawings**

# CHOLINE-SILICIC ACID COMPLEX WITH OSMOLYTES AND DIVALENT TRACE ELEMENTS

## CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 10/508,168 filed Apr. 7, 2005; which application is claims priority to International Application Serial No. PCT/EP03/03175 filed on Mar. 20, 2003, which application claims priority to European Application Serial No. 02076099.7 filed Mar. 20, 2002; the disclosures of which applications are herein incorporated by reference.

## FIELD OF THE INVENTION

The present invention relates to biological preparations, to a method for their preparation and to their use as nutrient and as medicament in the treatment of disorders and diseases.

It further relates to the use of a biological preparation as a plant nutrient and/or a fungal infection resistant agent, such as to decrease the concentration of pesticides and toxic compounds in the crop.

This patent application specifically relates to the use and preparation of special choline-(ortho)silicic acid complexes for plants, animals and humans.

## BACKGROUND OF THE INVENTION

Choline inhibits the gelification of highly concentrated orthosilicic acid (OSA) and oligomers at very low pH so that stable solutions ready for use can be prepared which are bioavailable for man, plant and animal. Polymers of OSA are huge molecules (also called macromolecules) formed from hundred or thousands of units called monomers (OSA) whereas oligomers are molecules of intermediate size—much larger than monomers but less than macromolecules (Brinker CJ et al, *Sol-Gel Science, The Physics and Chemistry of Sol-Gel processing*, Academic Press, Boston, p. 5)

Choline plays also an important role in fat metabolism of humans and animals and is part of all kind of living cells in the form of a phosphatidyl choline, an important phospholipid of our cell membrane. Humans synthesize choline from glycine, but this synthesis seems not to be enough for good health conditions all over the years. It is also present as acetylcholine, an important neurotransmitter. It is known as a vitamin B4. Moreover choline is an osmolyte and precursor of another important osmolyte, betaine. It is used as a food supplement in conditions as alcoholism, Alzheimer disease, angina pectoris, arteriosclerosis, asthma, cirrhosis of the liver, cystinuria, depression, diabetes, eczema, fatty liver, hair and nail problems, hepatitis, high cholesterol, hypertension, kidney liver damage, MS, etc. It is also related with the action of folate.

Although most people take enough through their food (as lecithin), there are reports that most people lack choline. A low intake of folate could be the reason for the shortness of choline in the body. Recent preliminary studies in rats show that choline could be involved in the osteogenesis and bone remodeling (Guglielmotti et al., *IADR 80 th General Session*, 2002) The daily intake of choline is estimated at 200-1000 mg/day. The national academy of sciences classified choline in 1998 as an essential nutrient (Institute of Medicine, Food and Nutrition Board, *Dietary reference Intake*, 1998, 390-422) after a study (Zeisel, 2000, *Nutrition*, 16, 669-671) showing that volunteers on a choline deficient diet were not

able to produce enough choline. It was observed that choline deficiency causes histopathological changes in the cartilage similar to those found in manganese deficient chicks, i.e. poor developments of bones, joints and cartilage. The inter-relationship of choline, methionine and betaine and their differences was recently reviewed (Workel et al., 1998, *World Poultry*, 14, 1998). Choline alone is needed as essential constituent for phospholipids, normal maturation of cartilage matrix of bone, and prevention of perosis in broilers.

The role of silicon in plants, animals and humans is well documented. It is known that orthosilicic acid is the biological active molecule and also that silicon in food and drinking water has to be processed into orthosilicic acid to be absorbed and transported in the organism. Orthosilicic acid, a very weak acid, is not very stable at all pH lower than 9.5 and quickly precipitates or forms sols or gels which are not so bioavailable for the organisms. It is therefore very difficult to prepare highly concentrated (>0.5% silicon) solutions of orthosilicic acid and oligomers convenient as stock solution for the different organisms.

In earlier patent applications (WO 95/21124) methods were described to prepare highly concentrated solutions, stable in time at different temperatures. These stock solutions are prepared, according to the preparation example, by hydrolysing a silicon source in an acid choline solution. Thereafter, the solution is neutralized by adding sodium hydroxide to a pH of 1.3 and purified over active carbon. The precipitate is filtered off and the solution is distilled under vacuum to obtain a preparation containing 3% by weight of silicon, 70% by weight choline hydrochloride and the rest water. According to formulation example A the neutralization can be carried out to a pH of 2.7-3.0. The bioavailability of the resulting stock solution is very high compared to other silicon compounds (silicates, clay, silica, horsetail, zeolites, . . . ), but those preparations are not stable after dilution.

## SUMMARY OF THE INVENTION

It is a first object of the present invention to provide a stock solution of orthosilicic acid and oligomers that is bioavailable, stable in time and dilutable, as well as a method of preparing such stock solution.

It is another object of the present invention to provide the use of such a stock solution for obtaining a diluted solution suitable for use for plants, animals and humans, and any resulting diluted solutions.

It is a further object of the present invention to provide use of said diluted solutions.

According to a first aspect, stock solutions are provided comprising orthosilicic acid and/or oligomers thereof, a primary ("constant/first") osmolyte choline and a weak alkalizing agent without free hydroxyl groups.

According to a second aspect a method for preparing a biological preparation, such as a stock solution, of orthosilicic acid and oligomers thereof and choline is provided, comprising:

hydrolyzing a silicon comprising choline solution thereby forming a choline stabilized orthosilicic acid and oligomers solution;

alkalinizing the choline orthosilicic acid and oligomers solution by adding a weak alkalizing agent without hydroxyl groups; and

optionally adding a divalent trace element and/or secondary osmolyte. According to a third aspect, a biological preparation is provided obtainable by

hydrolyzing a silicon comprising choline solution thereby forming a choline stabilized orthosilicic acid and oligomers solution;

alkalinizing the choline stabilized orthosilicic acid and oligomers solution by adding a weak alkalinizing agent without hydroxyl groups; and

optionally adding a divalent trace element and/or secondary osmolyte.

According to a fourth aspect, a biological preparation is provided comprising any such stock solution in diluted form.

According to a fifth aspect, use is provided of a biological preparation, particularly in diluted form, as a plant, animal or human nutrient or medicament, such as to fortify the plant against physical, chemical and biological stress conditions and aggression, and for use in animal and human against diseases related with bone, skin, cartilage, hair and nails, and connective tissue.

#### Preparation of the Stock Solution

The addition of  $\text{CaCO}_3$  or other carbonates (such as  $\text{MgCO}_3$ ,  $\text{MnCO}_3$  etc.) during the alkalization step in the preparation of SA-choline complex results in a stable solution (at low pH, particularly below pH 1) and is highly bioavailable. Addition of alkali with a free hydroxyl group (such as  $\text{NaOH}$ ,  $\text{KOH}$ , etc.) to increase the pH up to 0.5, results in gelification after 1 week to 3 months. On the contrary, the addition of  $\text{CaCO}_3$  or other carbonates to increase the pH give a solution with a stability of 2 years. We used also another compound for alkalization instead of carbonate: betaine, an osmolyte. Combinations of carbonates, such as  $\text{CaCO}_3$  and the osmolytes and combinations of betaine and other osmolytes were also possible.

#### Dilutions of the Stock Solution

It was not known that stable dilutions of these concentrated silicic acid stock solutions could be used in plants (t.g. spraying on plant leaves) or in drinking water of a wide range of animals (e.g. pigs, poultry, horses). Therefore, specific solutions with the choline-silicic acid complex in water have been tested and prepared properly for specific use and compared for bioavailability and physiological effects. Hereafter are described the specific preparations for plants, animals and humans and the unexpected results using these preparations of the invention.

Particularly, dilutions showing pH values up to 7.5 are sufficiently stable at silicon concentration lower than 0.07%, which is convenient for use as plant nutrient solution, animal drinking water or spray for animal food. It is further convenient for human drinking water.

#### Secondary Osmolytes

In experiments leading to the invention, preparations were developed in order to obtain long-term solution of concentrated bioavailable choline-silicic acid (SA)-osmolyte stock solutions and dilutions thereof such as nutrient solutions for plants and functional beverages for humans and animals. From all osmolytes tested only formulations with choline in combination with betaine, inositol, ethanolamine, glycine, taurine and monomeric sugars as mannitol, sorbitol result in acid stable solutions. Because betaine could even be more involved in the role of preserving healthy bones, cartilage, hair, nails and all kinds of GAG systems, it is a preferred osmolyte.

#### Use of Calcium and Trace Elements

The benefits of calcium for plants and animals are well documented in the literature (Poovaiah et al., 1988, *Hortscience*, 23, 267-71; Dell et al., 1987, *Handbook of Nutritionally Essential Mineral Elements*, Marcel Dekker, NY). It was not known that calcium is completely inert regarding OSA under pressure of choline and does not interfere with precipi-

tation or gelification reaction of highly concentrated SA. In the literature it is known that the addition of salts accelerate gel formation, in particular calcium ions are known to be very effective (Heald et al., 1955, *J Appl Chem London*, 5, 425) on polymerization of silicon.

After testing different combinations of  $\text{Ca}^{2+}$  and OSA, it was surprisingly found that  $\text{Ca}^{2+}$  does not interfere at pH-values < 0.7 with highly concentrated SA. Dilutions showing pH values up to 7.5 are sufficiently stable at silicon concentration lower than 0.07%, which is convenient for use as plant nutrient solution, animal drinking water or spray for animal food. The introduction of calcium as  $\text{CaCO}_3$  in the alkalization step in our preparation is therefore appropriate as carbonate ions will react with hydrogen ions resulting in a higher pH whereas the calcium ion itself will not react with hydrogen ions.

Other trace elements such as divalent ions as  $\text{Mn}^{2+}$ ,  $\text{Sr}^{2+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Cu}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Mg}^{2+}$  could be added at the same time in combination with  $\text{CaCO}_3$  during or after the alkalization step. Likewise other carbonates (such as  $\text{MgCO}_3$ ,  $\text{MnCO}_3$ ,  $\text{FeCO}_3$ ,  $\text{CuCO}_3$ ,  $\text{ZnCO}_3$ , etc.) can be used in the alkalization step as these will also increase the pH and result in stable solutions. The formation of chlorides and their solubility are the limiting factors.

The addition of  $\text{Zn}^{2+}$  is very interesting in animal applications because Zn is quickly eliminated from the body during the absorption of highly concentrated OSA so that an adequate Zn was the only element which was decreased in serum during OSA supplementation together with an inadequate Zn supplementation (low Zn diet). This observation is new and shows the importance of combining Zn with OSA during inadequate Zn supplementation. Interestingly, these results were not obtained in plants. The Zn concentration in plants was not affected after addition of concentrated OSA through sprays on the leaves. The SA-complex stock solution was diluted 1000 times and used as a spray for carrot plants during summertime (July and August). Carrots were analyzed for Si, Zn, Cu, Mg, Ca and Fe. There were no significant differences found for the metals except for Si which was doubled in concentration after spraying on the leaves once in a week.

## FORMULATIONS

All the formulations contain choline.

#### Formulation 1 with Calcium

Choline chloride is dried under vacuum and is treated with dry hydrochloric acid. Silicon (IV) tetrachloride is added to the formed acid choline solution (ratio  $\text{SiCl}_4$  versus choline chloride: 1 mol per 3 to 5 mol) at a temperature which is kept below 40° C.

For hydrolysis, water (ice/ice water) is added to the solution while cooling, wherein the temperature is held within the range of -10° C. to -30° C. A solution of 70-75% choline chloride in water is added to the hydrolysis solution in a ratio of 1 over 1. The resulting solution has a pH lower than 0 and a concentration of 0.7% Si by weight. Thereafter, this solution is alkalized by the addition of anhydrous calcium carbonate in a concentration of 50 g  $\text{CaCO}_3$  per liter. This results in a solution with pH 0.2.

Structure characterization using  $^{29}\text{Si}$ -NMR showed no signals between -30 and -70 ppm which is the spectral region for carbon bonded silicon (Si). The spectrum showed resonances around -72, -82, -92, -102 and -112 which are characteristic for  $\text{Q}^0$ ,  $\text{Q}^1$ ,  $\text{Q}^2$ , and  $\text{Q}^4$  species respectively.

## 5

Formulation 2 with Calcium and Zinc

A preparation as described in formulation 1 is prepared. ZnCl<sub>2</sub> is added after alkalization at a final concentration of 100 mg Zn/ml.

Formulation 3 with Betaine

Choline chloride is dried under vacuum and is treated with dry hydrochloric acid. Silicon (IV) tetrachloride is added to the formed acid choline solution (ratio SiCl<sub>4</sub> versus choline chloride: 1 mol per 3 to 5 mol) at a temperature which is kept below 40° C.

Solution A: For hydrolysis, water (ice/ice water) is added to the solution while cooling, wherein the temperature is held within the range of -10° C. to -30° C.

Solution B: A betaine solution is prepared in aqua destillata by adding to 1 liter of a.d. 1 to 1.5 kg of betaine.

1.8 liters of an aqueous 70-75% choline chloride solution is added to 2 liters of solution A. The resulting solution is alkalized by the addition 0.2 liter of solution B.

Formulation 4 with Calcium and Betaine

Choline chloride is dried under vacuum and is treated with dry hydrochloric acid. Silicon (IV) tetrachloride is added to the formed acid choline solution (ratio SiCl<sub>4</sub> versus choline chloride: 1 mol per 3 to 5 mol) at a temperature which is kept below 40° C.

Solution A: For hydrolysis, water (ice/ice water) is added to the solution while cooling, wherein the temperature is held within the range of -10° C. to -30° C.

Solution B: A betaine solution is prepared in aqua destillata by adding to 1 liter of a.d. 1 to 1.5 kg of betaine.

1.8 liters of an aqueous 70-75% choline chloride solution is added to 2 liters of solution A.

The resulting solution is alkalized by the addition of both 0.1 liter of solution B and anhydrous calcium carbonate (25 g CaCO<sub>3</sub> per liter).

Formulation 5 with Calcium and Taurine (100 mg/ml)

A preparation as described in formulation 1 is prepared. Taurine is added after alkalization at a final concentration of 100 mg taurine per milliliter.

Formulation 6 with Betaine and Sorbitol (300 mg/ml)

Choline chloride is dried under vacuum and is treated with dry hydrochloric acid. Silicon (IV) tetrachloride is added to the formed acid choline solution (ratio SiCl<sub>4</sub> versus choline chloride: 1 mol per 3 to 5 mol) at a temperature which is kept below 40° C.

For hydrolysis, water (ice/ice water) is added to the solution while cooling, wherein the temperature is held within the range of -10° C. to -30° C. A betaine solution is prepared in aqua destillata by adding to 1 liter of a.d. 1 to 1.5 kg of betaine.

Solution A: For hydrolysis, water (ice/ice water) is added to the solution while cooling, wherein the temperature is held within the range of -10° C. to -30° C.

Solution B: A betaine solution is prepared in aqua destillata by adding to 1 liter of a.d. 1 to 1.5 kg of betaine.

1.8 liters of an aqueous 70-75% choline chloride solution is added to 2 liters of solution A.

The resulting solution is alkalized by the addition 0.2 liter of solution B. Sorbitol is added after alkalization at a final concentration of 300 mg sorbitol per milliliter.

All preparations may also be combined with other divalent ions.

Formulation 7 of Diluted Composition

The formulations obtained in Formulation example 3 with 0.9% Si was diluted 500 times with tap water to obtain a Si concentration of 0.0018% and a pH of 6.5. The exact pH depends on the composition of the tap water, and the degree of dilution may vary, for instance between a ratio of 100 and 10000, preferably in the range of 200-1000. It will be clear

## 6

that the desired dilution ratio depends on the exact Si concentration of the stock solution and the intended Si concentration in the diluted solution, which will depend on the use (for plants, animals or humans), the frequency of use and the intention (as an additional nutrient or as a specific medication). After 1 year incubation at room temperature no sol or gel was found and the silicon concentration remained unchanged which indicated that this is a stable dilution. Sweeteners and other additives may be added to the diluted solution.

## EXAMPLES

## Example 1

## Increased Water Retention in Plants

A betaine-choline-SA preparation (0.9% Si) was diluted one over 500 and sprayed weekly on lettuce crops. Fields with crops of the same origin and which were kept in the same culture conditions, were at the same time sprayed with a control (water) and a herbal silica extract (*Equisetum arvense*). Several production parameters of the harvested crops were investigated to document production quality, such as head firmness, marketable field, total fresh weight and loss of weight (table 1). Treatment with betaine-choline-SA resulted in the highest fresh weight and marketable field. The quality of the harvested crops was also higher after betaine-choline-SA treatment since both the loss of weight was lower during conservation and the head firmness was increased compared to either control or herbal silica treatments. These results indicate that the application of betaine-choline-SA increases the water retention of the plant.

TABLE 1

Effect of betaine-choline-SA on the production of lettuce.

	Control		Betaine-choline-SA		Herbal silica	
	mean	rank(1)	Mean	rank(1)	mean	rank(1)
Head formation: (1-9)*	7	1	7	1	6.375	3
Head firmness: (1-9)*	5.375	2	5.5	1	4.75	3
Cut quality:	56.73	3	59.93	1	58.22	2
Marketable field kg/m <sup>2</sup> :	2.27	2	2.58	1	2.21	3
Left on field kg/m <sup>2</sup> :	2.34	2	2.19	3	2.37	1
Total fresh kg/m <sup>2</sup>	4.61	2	4.77	1	4.59	3
Loss of weight after 5 days:						
in cold store (4° C.):	4.4	2	3.48	1	5.35	3
at room temperature:	22.79	3	21.28	1	22.19	2
Loss of weight after 7 days:						
in cold store (4° C.):	7.55	2	5.38	1	8.18	3
at room temperature:	28.57	3	25.84	1	26.69	2
Sum of ranks		24		15		26

(1) Rank: 1 = best treatment, 2 = second best treatment, 3 = worst treatment

## Example 2

Increased Bone Density in Chicks Supplemented  
with Betaine-Choline-SA

Broiler chicks on a normal diet (1.4 mg Si/g) were supplemented with betaine-choline-SA (B-ch-SA) to investigate the effect of silicon on the serum calcium concentration and bone mineral content (BMC) density (BMD) in the femur.

A group of 42,500 chicks was administered B-ch-SA (13.5 mg Si/100 kg bodyweight/2 days) in their drinking water for 6 weeks which increased the total dietary Si intake with less than 0.5%. This physiological dose of 13.5 mg Si/100 kg bodyweight/2 days was obtained by diluting a stock solution of B-ch-SA (0.6% Si) in the drinking water of the chicks. The dilution factor was adapted to the bodyweight of the growing chicks throughout the experiment. A control group of 42,600 chicks of the same age was started in parallel with identical feeding but without B-ch-SA supplementation. Samples of 30 randomly chosen chicks were taken in each group at the age of six weeks to analyse the serum calcium concentration and femora. Femoral BMC and BMD were analyzed by Dual Energy X-ray Absorptiometry. Scans were recorded for both total femur and five regions of interest in the femur. Differences between means were evaluated with a one-tailed Student t-test.

The serum Ca concentration was significantly higher ( $p < 0.05$ ) in supplemented chicks ( $74.85 \pm 13.82$  mg/ml,  $n=60$ ) compared to controls ( $69.47 \pm 15.99$  mg/ml,  $n=60$ ).

The BMC was significantly higher for supplemented chicks compared to the controls in all the scanned areas of the femur. Total BMC was also significantly higher (+8.4%,  $p=0.016$ ) for supplemented chicks compared to controls.

The BMD was significantly higher at the midshaft (+4.25%,  $p=0.0209$ ), the distal metaphysis (+4.88%,  $p=0.0102$ ), and the hip region (+5.6%,  $p=0.014$ ) for supplemented chicks compared to controls.

Increasing the total dietary intake of broiler chicks with less than 0.5% in the form of B-ch-SA resulted in a significant higher serum calcium concentration and higher bone mass and density in cortical and trabecular bone of the femur.

## Example 3

## Reduced White Mold Infection in Carrots

A common fungal infection in carrots is white mold infection (*Erythra Heraclei*) of the leaves visualized as white spots. Fungicides are commonly used but have the disadvantage to be absorbed by the crops resulting in toxic or allergic reactions with the consumer.

A dilution of betaine-choline-SA was sprayed weekly on 3 different varieties of carrots (Nerac, Tyne, Napa) starting 3 months after sowing. Fields with crops of the same origin and kept at the same culture conditions were sprayed with fungicides.

Both crops treated with betaine-ch-SA and with fungicides showed remarkable less white spots on the leaves already one week after the treatment was started compared to the untreated control crops. This difference in affected leaves was observed until harvesting of the crop (see table 2).

TABLE 2

Yields of crops after betaine-ch-SA application		
Crops	Yield Kg/are	White mold infection score (1)
Untreated	654	2
betaine-ch-SA	751	6.5
Fungicides	775	7

(1) Score infection: 1 = severe infected, 9 = not infected

The production was found to be significantly higher after betaine-ch-SA treatment compared to untreated crops and comparable to crops which were treated with fungicides.

## Example 4

## Translocation of Silicon in Sweet Pepper

Sweet pepper was grown in a nutrient solution (hydraculture). Betaine-choline-SA was diluted 1 over 500 in the nutrient solution. Other plants of the same origin and kept at the same culture conditions, were not supplemented. The silicon concentration in leaves and roots was measured by atomic absorption spectrometry after 6 weeks supplementation. The silicon concentration in leaves was more than tenfold higher in leaves of plants supplemented with betaine-choline-SA compared to unsupplemented controls. These experiments clearly indicate that silicon from betaine-choline-SA is translocated from the root to the leaf.

## Example 5

## Reducing the Levels of Toxic Compounds in Plants

Pesticides are commonly used in the cultivation of crops to prevent or to treat fungal infections. However, the use of prophylactic agents has to be kept minimal due to their toxic nature for man, animals and the environment. Upper limits of residues are strictly regulated for the harvested crops and need to be as low as possible to guarantee the quality of the crop. Application of a calcium-choline-SA (see formulation I) dilution was found to:

- make the crop more resistant against fungal infection which permits the use of lower dosages of fungicides; and
- decrease the concentration of residues in the harvested crops.

## a) Lettuce

A calcium-choline-SA preparation was added to the pesticide solution in a concentration of 3 ml/10 L. Control plants were treated only with pesticides (see table A). Three days after seedlings were planted, foliar treatment was started and repeated 4 times. The period between treatments was each time 4 days. The crop was harvested three weeks after the last treatment and the concentration of residues (iprodione, dithiocarbamates) were analyzed.

TABLE A

Pesticide treatments	
Foliar treatment	Pesticide (dose)
1st treatment	80% thiram (30 g/L)
2nd	48% mancozeb, 10% metalaxyl (25 g/L)
3rd	50% iprodione (15 g/10 L)
4th	80% thiram (40 g/L) 50% primicarb (5 g/10 L)
5th	200 g/L cyanamid (15 ml/10 L)

The concentration of residues was significantly lower when crops were treated with calcium-choline-SA prepara-

tion: a decrease of more than 64% and 30% was found for dithiocarbamates and iprodione respectively (see table B). None of the crops were infected with fungi.

TABLE B

Residues of pesticides in lettuce treated with a calcium-choline-SA preparation.		
	Dithiocarbamates (mg/kg)	Iprodione (mg/kg)
Control: pesticides	14.6	2.45
Pesticides + calcium-choline-SA preparation	5.15	1.7

The silicon concentration was 45% higher in lettuce which was treated with calcium-choline-SA preparation (102 µg Si/g dry weight).

b) Potatoes

The incidence of Phytophthora infection was evaluated when combining a calcium-choline-SA preparation with a low dose of the commonly used fungicide Shirlan (fluazinam, 500 g/L). The minimal recommended dose of Shirlan is 0.4 liter per hectare to prevent Phytophthora infection of the crop. The crop remained healthy without a trace of Phytophthora infection when the fungicide dose was reduced with 50% and combined with 0.5 L calcium-choline-SA preparation per hectare, whereas untreated plots of plants were severely infected.

It is clear from the above examples that the new choline-SA preparations with in particular Ca and an osmolyte such as betaine, show very high bioavailability for plants and animals. These preparations may be used as nutrient and medicament for plant fortification and protection against different negative conditions (dry conditions, stress conditions from infections with microorganisms and insects). The preparations can be used for animals under a normal (silicon rich) diet. This means that these preparations (complex of choline-SA-osmolyte) are indeed active. They can therefore be used with good results for certain physiological conditions.

What is claimed is:

1. An acidic dilutable biological solution, the solution being dilutable with water and comprising:

bioavailable silicon comprising orthosilicic acid and silicic acid in a concentration of 0.9% or less; and

a primary osmolyte choline;

wherein the dilutable solution is acidic with a pH<1, is stable against gelification and is prepared by a method comprising:

(a) hydrolyzing a silicon comprising choline solution to produce a choline stabilized orthosilicic acid and oligomers solution; and

(b) alkalizing the choline stabilized orthosilicic acid and oligomers solution by adding a weak alkalizing agent without hydroxyl groups selected from the group of consisting of carbonates, betaine and combinations thereof.

2. The dilutable biological solution according to claim 1, wherein the weak alkalizing agent is a carbonate.

3. The dilutable biological solution according to claim 2, wherein the carbonate is calcium carbonate (CaCO<sub>3</sub>).

4. The dilutable biological solution according to claim 1, wherein the preparation of the solution further comprises adding a concentrated choline solution to the choline stabilized orthosilicic acid and oligomers solution prior to alkalization.

5. The dilutable biological solution according to claim 1, further comprising a secondary osmolyte.

6. The dilutable biological solution according to claim 5, wherein the secondary osmolyte is selected from the group consisting of betaine, glycine, taurine, carnitine, inositol, ethanolamine, phosphates thereof and mono sugars and combinations thereof.

7. The dilutable biological solution according to claim 1, further comprising a divalent trace element.

8. The dilutable biological solution according to claim 7, wherein the divalent trace element is selected from the group consisting of Cu, Mn, Mg, Sr, Zn, Ca and Fe and combinations thereof.

9. The dilutable biological solution according to claim 5, further comprising a divalent trace element.

10. The dilutable biological solution according to claim 9, wherein the divalent trace element is selected from the group consisting of Cu, Mn, Mg, Sr, Zn, Ca and Fe and combinations thereof.

11. A diluted plant nutrient solution, the diluted plant nutrient solution prepared by a method comprising:

diluting a water dilutable biological solution of bioavailable silicon with a diluent to produce the plant nutrient solution, wherein the dilutable biological solution is a solution prepared by a method comprising:

hydrolyzing a silicon comprising choline solution to produce a choline stabilized orthosilicic acid and oligomers solution; and

alkalinizing the choline stabilized orthosilicic acid and oligomers solution by adding a weak alkalizing agent selected from the group consisting of carbonate and betaine and combinations thereof;

wherein the diluted plant nutrient solution has a silicon concentration of 0.07% or less, said silicon being in bioavailable form, and a pH of 7.5 or less.

12. The diluted plant nutrient solution according to claim 11, wherein the water dilutable biological solution is selected from the group consisting of:

(i) a solution comprising bioavailable silicon comprising orthosilicic acid and silicic acid, a primary osmolyte choline, and a weak alkalizing agent without hydroxyl groups, wherein the weak alkalizing agent is a carbonate, betaine or combinations thereof and which dilutable solution is acidic with a pH<1 and is stable against gelification, the pH being controlled by means of the weak alkalizing agent;

(ii) an acidic solution comprising bioavailable silicon in the form of orthosilicic acid and silicic acid in a concentration of 0.9% or less and a pH<1 and stable against gelification, a primary osmolyte choline, and a divalent trace element; and

(iii) an acidic solution comprising bioavailable silicon in the form of orthosilicic acid and silicic acid in a concentration of 0.9% or less and a pH<1 and stable against gelification, a primary osmolyte choline, and a secondary osmolyte.

13. A spray for animal food, the spray prepared by a method comprising:

diluting a water dilutable biological solution of bioavailable silicon with a diluent to produce the spray, wherein the dilutable biological solution is a solution prepared by a method comprising:

hydrolyzing a silicon comprising choline solution to produce a choline stabilized orthosilicic acid and oligomers solution; and

alkalinizing the choline stabilized orthosilicic acid and oligomers solution by adding a weak alkalizing

## 11

agent selected from the group consisting of carbonate and betaine and combinations thereof;  
 wherein the spray has a silicon concentration of 0.07% or less, said silicon being in bioavailable form, and a pH of 7.5 or less.

**14.** The spray according to claim **13**, wherein the water dilutable biological solution is selected from the group consisting of:

- (i) a solution comprising bioavailable silicon in the form of orthosilicic acid and silicic acid, a primary osmolyte choline, and a weak alkalizing agent without hydroxyl groups, wherein the weak alkalizing agent is a carbonate, betaine or combinations thereof and which dilutable solution is acidic with a pH<1 and is stable against gelification, the pH being controlled by means of the weak alkalizing agent;
- (ii) an acidic solution comprising bioavailable silicon in the form of orthosilicic acid and silicic acid in a concentration of 0.9% or less and a pH<1 and stable against gelification, a primary osmolyte choline, and a divalent trace element; and
- (iii) an acidic solution comprising bioavailable silicon in the form of orthosilicic acid and silicic acid in a concentration of 0.9% or less and a pH<1 and stable against gelification, a primary osmolyte choline, and a secondary osmolyte.

**15.** A drinking solution, the drinking solution prepared by a method comprising:

diluting a water dilutable biological solution of bioavailable silicon with a diluent to produce the drinking solution, wherein the dilutable biological solution is a solution prepared by a method comprising:

hydrolyzing a silicon comprising choline solution to produce a choline stabilized orthosilicic acid and oligomers solution; and

alkalinizing the choline stabilized orthosilicic acid and oligomers solution by adding a weak alkalizing agent selected from the group consisting of carbonate and betaine and combinations thereof;

wherein the drinking solution has a silicon concentration of 0.07% or less, said silicon being in bioavailable form, and a pH of 7.5 or less.

**16.** The drinkable solution according to claim **15**, wherein the water dilutable biological solution is selected from the group consisting of:

- (i) a solution comprising bioavailable silicon comprising orthosilicic acid and silicic acid, a primary osmolyte choline, and a weak alkalizing agent without hydroxyl

## 12

groups, wherein the weak alkalizing agent is a carbonate, betaine or combinations thereof and which dilutable solution is acidic with a pH<1 and is stable against gelification, the pH being controlled by means of the weak alkalizing agent;

- (ii) an acidic solution comprising bioavailable silicon comprising orthosilicic acid and silicic acid in a concentration of 0.9% or less and a pH<1 and stable against gelification, a primary osmolyte choline, and a divalent trace element; and

- (iii) an acidic solution comprising bioavailable silicon in the form of orthosilicic acid and silicic acid in a concentration of 0.9% or less and a pH<1 and stable against gelification, a primary osmolyte choline, and a secondary osmolyte.

**17.** A method of providing plant protection or increasing mineral strength in animals comprising:

diluting a composition according to claim **1**; and

administering the diluted solution to a plant or animal or human.

**18.** The method according to claim **17**, wherein the diluted solution is administered to a plant as a nutrient, to aid the plant in resisting fungal infections or to fortify the plant against physical, chemical and biological stress conditions and aggression.

**19.** The method according to claim **17**, wherein the diluted solution is administered to an animal to treat a disease selected from the group of the bone, skin, cartilage, hair, nails and connective tissue diseases.

**20.** A method for preparing a dilutable biological solution comprising bioavailable silicon in a concentration of 0.9% or less, the method comprising:

- a) hydrolyzing a silicon comprising choline solution to produce a choline stabilized orthosilicic acid and oligomers solution; and

- b) alkalizing the choline orthosilicic acid and oligomers solution with a weak alkalizing agent without hydroxyl groups selected from the group of carbonate and betaine, wherein the dilutable solution is acidic with a pH<1 and is stable against gelification, the pH being controlled by means of the weak alkalizing agent.

**21.** The method according to claim **20**, wherein a concentrated choline solution is added to the choline stabilized orthosilicic acid and oligomers solution prior to alkalizing.

\* \* \* \* \*